Drug and Narcotic Control

"Drug and Narcotic Control" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Control of drug and narcotic use by international agreement, or by institutional systems for handling prescribed drugs. This includes regulations concerned with the manufacturing, dispensing, approval (DRUG APPROVAL), and marketing of drugs.

Descriptor ID	D004335
MeSH Number(s)	I01.880.604.605.250 N03.706.615.402.250 N04.452.706.310
Concept/Terms	Drug and Narcotic Control Drug and Narcotic Control Narcotic and Drug Control Pharmaceutical Policy Pharmaceutical Policy Pharmaceutical Policies Policies, Pharmaceutical Policy, Pharmaceutical Pharmaceutic Policy Narcotic Control Narcotic Control Control, Narcotic Controls, Narcotic Narcotic Controls Drug Control Drug Control Control, Drug Controls, Drug Drug Controls Drug Regulations Drug Regulations Drug Regulation Regulation, Drug Regulations, Drug

Below are MeSH descriptors whose meaning is more general than "Drug and Narcotic Control".

Anthropology, Education, Sociology and Social Phenomena [I]
Social Sciences [I01]
Sociology [I01.880]
Social Control, Formal [I01.880.604]
Legislation, Drug [I01.880.604.605]
Drug and Narcotic Control [I01.880.604.605.250]
Health Care [N]
Health Care Economics and Organizations [N03]
Social Control, Formal [N03.706]
Legislation as Topic [N03.706.615]
Legislation, Drug [N03.706.615.402]
Drug and Narcotic Control [N03.706.615.402.250]
Health Services Administration [N04]
Organization and Administration [N04.452]
Pharmacy Administration [N04.452.706]
Drug and Narcotic Control [N04.452.706.310]

Below are MeSH descriptors whose meaning is related to "Drug and Narcotic Control".

Below are MeSH descriptors whose meaning is more specific than "Drug and Narcotic Control".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug and Narcotic Control" by people in this website by year, and whether "Drug and Narcotic Control" was a major or minor topic of these publications.

Bar chart showing 23 publications over 16 distinct years, with a maximum of 3 publications in 2007 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
1999	1	0	1
2000	1	0	1
2001	2	0	2
2003	1	0	1
2004	0	1	1
2005	1	0	1
2006	1	0	1
2007	3	0	3
2011	1	1	2
2014	1	1	2
2015	1	0	1
2016	2	1	3
2017	1	0	1
2019	1	0	1
2024	0	1	1

Below are the most recent publications written about "Drug and Narcotic Control" by people in Profiles.

Englander H, Chappuy M, Krawczyck N, Bratberg J, Potee R, Jauffret-Roustide M, Rolland B. Comparing methadone policy and practice in France and the US: Implications for US policy reform. Int J Drug Policy. 2024 Jul; 129:104487.

View in: PubMed
Aulet RM, Trieu V, Landrigan GP, Millay DJ. Changes in Opioid Prescribing Habits for Patients Undergoing Rhinoplasty and Septoplasty. JAMA Facial Plast Surg. 2019 Dec 01; 21(6):487-490.

View in: PubMed
Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D. Kratom policy: The challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019 08; 70:70-77.

View in: PubMed
Tran S, Lavitas P, Stevens K, Greenwood BC, Clements K, Alper CJ, Lenz K, Price M, Hydery T, Arnold JL, Takeshita M, Bacon R, Peristere JP, Jeffrey PL. The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population. J Manag Care Spec Pharm. 2017 May; 23(5):532-539.

View in: PubMed
Gabay M, Smith JA, Chavez ML, Goldwire M, Walker S, Coon SA, Gosser R, Hume AL, Musselman M, Phillips J, Abe AM. White Paper on Natural Products. Pharmacotherapy. 2017 01; 37(1):e1-e15.

View in: PubMed
Kortenkamp A, Bourguignon JP, Slama R, Bergman ?, Demeneix B, Ivell R, Panzica G, Trasande L, Zoeller RT. EU regulation of endocrine disruptors: a missed opportunity. Lancet Diabetes Endocrinol. 2016 08; 4(8):649-650.

View in: PubMed
Bourguignon JP, Slama R, Bergman ?, Demeneix B, Ivell R, Kortenkamp A, Panzica G, Trasande L, Zoeller RT. Science-based regulation of endocrine disrupting chemicals in Europe: which approach? Lancet Diabetes Endocrinol. 2016 08; 4(8):643-646.

View in: PubMed
Lamy FR, Daniulaityte R, Sheth A, Nahhas RW, Martins SS, Boyer EW, Carlson RG. "Those edibles hit hard": Exploration of Twitter data on cannabis edibles in the U.S. Drug Alcohol Depend. 2016 Jul 01; 164:64-70.

View in: PubMed
Luiza VL, Chaves LA, Silva RM, Emmerick IC, Chaves GC, Fonseca de Ara?jo SC, Moraes EL, Oxman AD. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database Syst Rev. 2015 May 08; (5):CD007017.

View in: PubMed
Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014 Dec; 49(6):1964-79.

View in: PubMed

People

Explore

Similar Concepts

Top Journals